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Summary
Background: The toxicity profile of prolonged infusions of
paclitaxel in combination with cyclophosphamide in metastat-
ic breast cancer has already been defined. The objective of this
dose-finding study was to determine the maximum tolerable
doses (MTDs) of shorter (three-hour) infusions of paclitaxel in
combination with i.v. bolus cyclophosphamide in patients who
had previously received a maximum of one chemotherapy for
advanced breast carcinoma. The MTD of the same regimen
with granulocyte colony-stimulating factor (G-CSF) support
was then established.
Patients and methods: Eighty women with metastatic breast
cancer received a total of 352 fully evaluable courses of ther-
apy. The starting doses were paclitaxel 135 mg/m2 and cyclo-
phosphamide 750 mg/m2 given every three weeks. At least
three patients were treated at each dose level and if there were
dose-limiting toxic effects during the first cycles three addi-
tional patients were entered. G-CSF support (5 ug/kg s.c.) was
added to the second cycle if specific dose-limiting toxicities
had occurred during the first cycle. The MTD was defined as
the dose level at which more than two of six patients presented
dose-limiting toxicities during the first cycle.
Results: Febrile neutropenia (n = 4) and severe thrombo-
cytopenia (n - 1) defined the MTDs of paclitaxel as 200 mg/
m2 and of cyclophosphamide as 2,000 mg/m2 with or without
G-CSF in patients with and, respectively, without prior chemo-
therapy for advanced disease. Non-hematologic toxicity was
moderate. Recommended doses were 200 mg/m2 of paclitaxel
and 1,750 mg/m2 of cyclophosphamide with or without G-CSF
in patients with and, respectively, without prior chemotherapy.
The overall response rate was 25% and 50%, respectively, in
patients with and without prior chemotherapy for metastatic
disease. Complete remissions (9%) were reported only in
patients without prior chemotherapy; antitumour activity in
women with anthracycline-resistant disease, with an 8% re-
sponse rate (95% CI: l%-26%), was poor.
Conclusions: Paclitaxel at 200 mg/m2 and cyclophospha-
mide at 1,750 mg/m2 can be safely administered every three
weeks to women with advanced breast cancer. The moderate
antitumour activity observed with the schedule tested argues
against its use as initial therapy for advanced breast cancer.
Key words: breast cancer, cyclophosphamide, G-CSF, pacli-
taxel
Introduction
Paclitaxel (P) has shown good antitumor activity in
metastatic breast cancer, with results comparable to
those achieved with anthracyclines [1, 2]. As first-line
therapy, treatment with P given over 24 hours at doses
between 200 and 250 mg/m2 resulted in an overall
response rate of 50%-60%, and a response rate of 20%-
30% has been reported in patients treated at dosages
between 175 mg/m2 and 250 mg/m2 as 3-hour or 24-
hour infusions [3, 4]. Several trials were then designed to
develop synergistic combinations with agents known to
be active in breast cancer. The most extensively studied
and thus far most promising of these is the one with
doxorubicin. The observation that grade 3-4 mucositis
was more frequent when P preceded doxorubicin, first
reported by Holmes with P given as 24-hour infusion [5],
was confirmed in subsequent studies [6], where an over-
all response rate between 50% and 80% was reported.
Gehl et al. [7] and Gianni et al. [8] then reported
response rates exceeding 80% in patients receiving P as
a three-hour infusion in combination with bolus doxo-
rubicin as initial treatment for metastatic breast cancer.
The observation that the sequence of administration
had no significant effect on the toxicity profile [8] and
that severe cardiotoxicity with congestive heart failure
occurred in 25% of patients after a cumulative dose of
480 mg/m2 of doxorubicin, raised the issue of the cumu-
lative dose and optimal scheduling of the anthracycline.
Cyclophosphamide (C) is the other candidate for
combination studies with P because it is the standard
alkylating agent used in both the adjuvant and the
palliative settings, no mechanisms of cross-resistance
with P are known, and neutropenia, the major over-
lapping toxic effect of the two drugs, could be amelio-
rated by the use of colony-stimulating factors. Results
of two phase I trials evaluating the combination of P
and C in metastatic breast cancer have already been
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published. In the Johns Hopkins trial, P was given over
24 hours with intravenous bolus C and G-CSF support
to patients with at least one prior chemotherapy for
metastatic disease [9]. Neutropenia and typhlitis were
dose-limiting (DLT) and the maximum tolerable doses
(MTDs) were 200 mg/m2 of P and 1,250 mg/m2 of C.
Sequence-dependent toxicities were observed, the se-
quence P/C being associated with deeper neutropenia
and higher admission rate for neutropenic fever; phar-
macokinetic interactions between the two drugs were
not observed.
In the study conducted at the NCI by Tolcher et al., P
was given over 72 hours with high-dose C, spread over
three consecutive days, and G-CSF to patients mostly
pretreated for metastatic disease with C and/or an
anthracycline-containing regimen [10]. Myelosuppres-
sion was DLT and MTDs were established at 160 mg/
m2 of P and 2,700 mg/m2 of C.
The primary objective of this study was to determine
the MTD of the combination of P given by three-hour
infusion and C in patients with advanced breast cancer.
In a subsequent phase of the study the MTD of the same
combination with G-CSF support was determined. The
evaluation of the antitumor efficacy was a secondary
endpoint of this trial, which was primarily a dose-find-
ing study.
Patients and methods
Eligibility criteria
Patients with histologically or cytologically documented metastatic
breast cancer who had received no more than one therapy regimen for
advanced disease were eligible. One additional adjuvant treatment was
acceptable if the time interval between the adjuvant and the chemo-
therapy for metastatic disease was longer than one year. Prior hor-
monal therapy for advanced disease was allowed if it had been
discontinued at least four weeks before study entry. Eligibility criteria
also included age younger than 75 years, an Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or less, adequate
hematologic function (absolute neutrophil count ANC >2.0 x 109/l,
platelet count > 100 x 109/l), and normal renal and hepatic function.
With respect to prior anthracyclines, a cumulative dose of <550
mg/m2 doxorubicin or an equivalent dose of another anthracycline,
anthrapyrazole or anthracene, was permitted. Written informed patient
consent was required. Pre-existing motor or sensory neuropathy of
World Health Organisation (WHO) grade >2 and a history of ar-
rhythmias or congestive heart failure, even if medically controlled,
were considered exclusion criteria.
Study treatment
Paclitaxel was supplied by the Bristol-Myers Squibb Company as 5 ml
vials containing a concentrated sterile solution 6 mg/ml in polyoxy-
ethylated castor oil 50% and dehydrated alcohol USP 50%. The
calculated amount was diluted in 500 ml 0.9% saline solution and
administered as a three-hour infusion. For administration, in-line
filters (0.2 u) (IVEX-2; Abbott Laboratories, Abbott Park, IL), glass
containers, and polyethylene-lined nitroglycerin tubing were used.
Premedication consisted of dexamethasone 20 mg orally 12 and 6
hours before administration plus ranitidine 50 mg and dimethindene 8
mg i.v. 30 minutes before P. Cyclophosphamide was administered
diluted in 250 ml of 0.9% saline solution as a 30 min infusion following
P. At least 1,500 ml of 0.9% normal saline was given as post-treatment
hydration after a dose of C of at least 1,500 mg/m2. Prophylaxis
against hemorrhagic cystitis with mesna was not routinely applied.
Prophylactic antiemetic treatment was given according to investiga-
tors' routine practice; the recommended regimen included i.v. 5HT3
antagonists and steroids the day of treatment followed by oral meto-
clopramide or thiethylperazine for the prevention of delayed emesis.
G-CSF was provided by Amgen (Thousand Oaks, CA) as a 1 ml vial
300 ug/ml aqueous solution. When indicated, G-CSF 5 ug/kg/d was
given s.c. from day 2 until day 19 or until the ANC was at least 2.0 x
lO'/l on two consecutive occasions, or until the ANC was 5.0 x 109/l,
whichever occurred first. Prophylactic oral antibiotics, started when-
ever the ANC fell below 0.5 x 109/l and continued until the ANC had
recovered to at least 1.0 x 109/l, were recommended. Ciprofloxacin 500
mg b.i.d. was the most frequently used treatment. Chemotherapy was
repeated every three weeks provided the ANC was > 2.0 x io'/l and
the platelet count was > 100 x 1O9/1. If recovery had not occurred after
a treatment delay of a maximum of three weeks patients were with-
drawn from the study.
Study design
The starting doses of P and C were 135 mg/m2 and 750 mg/m2,
respectively. The dose of 135 mg/m2 of P was selected on the basis of
the available data on tolerability and antitumor activity of mono-
chemotherapy in previously treated patients. The dose of C of 750 mg/
m2 was within the recommended range (600 to 1,000 mg/m2) for this
agent when administered in combination with antitumour drugs such
as doxorubicin and/or 5-fluorouracil. Doses of both drugs were esca-
lated sequentially by 15% increments in each successive cohort of new
patients. Intra-individual dose escalation was not permitted. At least
three patients had to be treated at each dose level, and if DLTS were
observed in the three weeks following the first administration, three
additional patients had to be entered at the same dose level. If DLTs
were overall reported in more than two of six patients the MTD was
considered to have been reached and dose escalation was discontinued.
WHO criteria for toxicity were applied [11].
Dose modifications and G-CSF support
In all patients, G-CSF support was added at the next cycle in in-
stances, during the previous course, of an ANC <0.5 x 109/l for more
than seven days or an ANC <0.1 x 109/l for more than three days,
febrile neutropenia requiring i.v. antibiotics, WHO > grade 3 muco-
sitis for more than seven days, or failure of ANC recovery by day 28. If
in more than two of six patients there was the indication to add G-CSF
support, because of occurrence of those DLTs in the three weeks
following the first administration, G-CSF was given routinely already
at the first cycle in patients being treated for the first time at the next
higher dose level; at this stage, the second phase of the study, aiming at
defining the MDT with G-CSF support, began. The doses of P and C
were decreased by one level during subsequent cycles if a patient
presented one of the DLTs for which G-CSF support was not indicated
or if the patient, despite G-CSF support, again presented a DLT for
which G-CSF support was indicated.
Definition of MTD
The MTD was reached if after the first cycle more than two patients
presented a DLT that required G-CSF support or a DLT for which
G-CSF was not indicated (i.e., platelet count <25 x 1O9/1 requiring
platelet transfusion, WHO ~z grade 3 nonhematologic toxicity except
for alopecia, nausea and vomiting, and grade 3 musculoskeletal pain)
or persistence of WHO > grade 2 nonhematologic toxicity (with the
exception of alopecia, nausea and vomiting, and musculoskeletal pain)
at scheduled retreatment. Identical criteria were applied to define the
MTD of the second phase of the study with G-CSF support.
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Disease evaluation and treatment duration
It was required that baseline evaluations, including history, physical
examination, complete blood cell count, biochemistry, electrocardio-
gram, chest X-ray, and radiologic imaging of indicator lesions, be
earned out within two weeks prior to study entry. Echocardiography
was performed in patients with a cumulative doxorubicin dose > 300
mg/m2. During therapy, complete blood cell counts were performed at
least twice _weeldy_and biochemistry-evaluations before «acb cycler
Assessment of tumour response was performed after the first two
cycles in the absence of clinical evidence of early tumour progression,
and every two courses thereafter. The WHO criteria for response were
applied [11]. Responses had to be confirmed by a subsequent evalua-
tion performed after at least four weeks. Patients with progressive
disease went off study, while in responders treatment had to be
continued until relapse, unacceptable toxicity, or for four cycles after
achievement of complete (CR) or partial response (PR). To avert
cumulative non-hematologic toxicity, a maximum of 10 cycles was
given. In patients with stable disease (SD) treatment could be con-
tinued for up to six cycles at the discretion of the investigator. The
duration of response was calculated from the start of treatment.
Table 1 Patient characteristics.
Prior anthracychnes
Anthracycline-resistant
No. of patients
Entered
ECOG performance status
0-1
2
Dominant disease site
Liver
Lung
No. of metastatic sites
1
2
2*3
Prior CT
Adjuvant only
Metastatic disease only
Both
80
73
7
35
24
38
31
11
28
17
19
49
25
Results
From September 1992 to June 1996, 80 patients with
advanced breast cancer entered the study (Table 1).
Their median age was 49.5 years (range 27 to 70 years),
and in 91% the performance status was 0—1. Dominant
site of disease, defined as the metastatic site most rel-
evant in the evaluation of antitumour efficacy, was liver
in 43%; 52% of the patients had at least two metastatic
sites and 43% had already received one chemotherapy
regimen for advanced disease. One young patient,
treated with P at 200 mg/m2 and C at 1750 mg/m2, had
received adjuvant high-dose chemotherapy with periph-
eral stem cell transplantation 11 months before entering
the protocol. Only 16 patients had received no prior
chemotherapy. Forty-three percent of the patients had
undergone radiotherapy, either complementary to pri-
mary surgery or for metastatic disease, and 56% had
received previous hormonal therapy, in 82% for meta-
static disease.
Of 49 patients (61%) pretreated with anthracyclines,
25 were considered anthracycline-resistant because of
tumour relapse within six months from the last doxo-
rubicin administration (10 patients), tumour progression
after an initial response (seven patients) and tumour
progression while on anthracycline without an interven-
ing response (eight patients). Forty-nine patients (61%)
were pretreated with C.
A total of 382 courses of therapy were administered,
of which 352 (92%) were fully evaluable for hematologic
toxicity. The doses of P and C were escalated through 10
dose levels from 135 to 200 mg/m2 of P and 600 mg/m2
to 2,000 mg/m2 of C (Table 2). The median number of
cycles administered to all patients was 5 (range 1 to 10);
two patients discontinued treatment after one cycle due
to early progression of disease, one patient died of tox-
icity after the first cycle and one patient refused therapy
after the first course. All patients were evaluable for
toxicity.
Table 2 Dose escalation.
Dose
level
P/C dose
(mg/m2)
Prior CT°
pts/cycles
No prior CT*
pts/cycles
Total eval.
pts/cycles
1
2
3
4
5
6
7
8
9
10
135/750
155/750
175/600
175/750
200/750
200/1000
200/1250
200/1500
200/1750
200/2000
3/8
5/17
3/8
4/11
3/13
3/19b
3/15
3/17
6/31
6/27
0/0
1/4
1/4
3/24
6/28
6/30
3/17
5/26
14/81
2/12
3/8
6/20
4/12
7/35
9/41
9/36
6/31
8/36
20/97
8/36
* CT - chemotherapy for advanced disease.
b
 G-CSF given from the first cycle.
Hematologic toxicity
Neutropenia was the main toxicity, with an overall
median ANC nadir of 0.4 x 109/l (range 0 to 9 x 1O9/1)
and a median time to ANC nadir of 12 days (range 5 to
32 days). Grade 4 neutropenia occurred at all dose
levels; overall, febrile neutropenia occurred in 5% of
cycles and the incidence of febrile neutropenia was
similar at all dose levels except at the highest (P/C 200/
2,000 mg/m2), where 20% of cycles were associated with
neutropenic fever. Documented infections were uncom-
mon and never severe.
The most relevant features of hematologic toxicity
per dose level in patients pretreated or non-pretreated
with chemotherapy for advanced disease are reported in
Tables 3 and 4, respectively.
No distinctions were made at the lowest dose levels
between patients pretreated or not for advanced disease.
Of six patients treated at dose level 2 (P/C 155/750 mg/
m2), two had an ANC below 0.1 x 1O9/1 for more than
three days, one after the first cycle and one after the
second cycle. In the first patient, a 70-year-old pre-
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Table 3 Hematologic toxicity in patients pretreated with chemotherapy for advanced disease.
Dose
level
2
3
4
5
6
7
8
9
10
Dose P/C
(mg/m2)
155/750
175/600
175/750
200/750
200/1000
200/1250
200/1500
200/1750
200/2000
Eval ua-
ble pts/
cycles
5/17
3/8
4/11
3/13
3/9
3/14
3/15
6/27
6/24
ANC
nadir
median
0.26
0.18
0.35
0.32
2.7*
1.1*
1.2'
0.3*
0.35*
x 109/l
range
0.01-2.1
0.05-1.5
0 04-0.8
0.01-2.6
0.2-5.7
0.13-3.7
0.06-9.0
0.01-2.3
0-3.0
Days ANC
<0.5
(median)
2
3.5
4
2
0
0
0
1
3
Pts with
G3/4 neu-
tropenia
(all cycles)
1/3
0/2
1/3
0/3
0/1
0/2
1/1
1/5
0/6
Pit nadir
median
134
192
197
157
91
151
171
134
81
x lO'/l
range
15-331
90-292
163-305
105-230
46-150
38-216
57-248
42-230
9-211
Pts with G3/4
thrombopenia
(all cycles)
0/1
0/0
0/0
0/0
1/0
1/0
0/0
1/0
1/2
DLTs
(cycle 1)
l b
2C
3 d
DLTs
(all
cycles)
3
2
4
Abbreviation: DLT - dose-limiting toxicity.
* G-CSF given from the first cycle.
b
 ANC <0.1 x lO'/l > 3 days.
c
 Febrile neutropenia and ANC <0.1 x lO'/l > 3 days in 1 pteach.
d
 Febrile neutropenia in 2 pts and grade 4 thrombocytopenia in 1 pt.
Table 4. Hematologic toxicity in patients non-pretreated with chemotherapy for advanced disease.
Dose
level
1
2
3
4
5
6
7
8
9
10
Dose P/C
(mg/m2)
135/750
155/750
175/600
175/750
200/750
200/1000
200/1250
200/1500
200/1750
200/2000
Evalua-
ble pts/
cycles
3/8
1/3
1/4
3/24
6/28
6/27
3/17
5/21
14/70
2/12
ANC
nadir
median
0.3
0.9
0.26
0.59
0.51
0.5
0.55
0.5
0.3
0.31
x 109/l
range
0.2-1.2
0.7-1.6
0.09-0.3
0.13-2.6
0.01-4.0
0.02-2.2
0.1-2.2
0-1.8
0-1.6
0.02-2.8
Days ANC
<0.5
(median)
4.5
0
3
0
0
0
0
0
4.5
3
Pts with
G3/4 neu-
tropenia
(all cycles)
0/3
1/0
0/1
0/3
2/4
2/4
1/2
1/4
0/14
0/2
Pit nadir
median
163
174
137
202
235
228
195
231
170
141
x 109/l
range
77-269
166-413
125-155
115-340
75-340
143-289
152-271
130-350
15-304
57-383
Pts with G3/4
thrombopenia
(all cycles)
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/0
0/2
0/0
DLTs
(cycle 1)
1*
2 "
DLTs
(all
cycles)
1
2
Abbreviation: DLT - dose-limiting toxicity.
* Toxic death during grade 4 neutro- and thrombocytopenia.
b
 Febrile neutropenia in 2 pts.
treated woman with bone metastasis, severe myelotox-
icity developed after the third cycle despite the addition
of G-CSF during the second cycle as per protocol. The
patient presented acute dyspnea and died nine days after
P with grade 4 anemia, neutropenia and thrombocyto-
penia, without clinical signs of infection or bleeding;
post-mortem examination was not performed, and myo-
cardial infarction or lung embolism could not be ruled
out.
Because of the neutropenia observed, the dose of P
was escalated to 175 mg/m2 while C was decreased to
600 mg/m2 at dose level 3, without the occurrence of
hematologic DLTs. At dose level 5, two of three patients
pretreated for advanced disease required G-CSF sup-
port at the second cycle (due to febrile neutropenia in
one case and to an ANC below 0.1 x 1O9/1 for more than
three days in the other) (Table 3); G-CSF was added
during the first cycle in pretreated patients from dose
level 6 (P/C 200/1,000 mg/m2). It was also decided not
to escalate further the dose of P to avoid cumulative
neurotoxicity. No DLTs were encountered up to a C dose
of 2,000 mg/m2 (dose level 10) where three of six patients
developed DLTs consisting of febrile neutropenia in two
cases and grade 4 thrombocytopenia in 1.
In patients non-pretreated for advanced disease
(Table 4) the dose of C was increased without the
addition of G-CSF up to 2,000 mg/m2 where the first
two patients suffered at the first cycle DLTs for which
G-CSF was indicated. The MTDs of P and C were
therefore 200 mg/m2 and, respectively, 2,000 mg/m2 of
C with or without G-CSF in patients with and, respec-
tively, without prior chemotherapy; the recommended
doses of P and C were 200 mg/m2 and, respectively,
1,750 mg/m2, with G-CSF support only in pretreated
patients.
A total of 20 patients, either pretreated or not were
then entered at the recommended dose to better define
toxicity and antitumour activity. Thrombocytopenia was
of lower degree than neutropenia and more pronounced
in patients who had previously received chemotherapy
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(Tables 3 and 4). A 65-year-old patient with lung metas-
tasis previously untreated with chemotherapy developed
dizziness and confusion after the first cycle at dose level
9 associated with grade 4 neutro- and thrombocyto-
penia. No signs of infection or septic shock were
present, renal and liver function test results were within
the normal ranges, while an uncontrolled diabetes mel-
litus was treated without objective improvement. CNS
bleeding was clinically diagnosed but the patient died
before any further examination could be performed;
postmortem examination was not permitted by the fam-
ily.
Overall, hematologic toxicity was not cumulative
without a significant increase of DLTs after repeated
administrations.
RBC transfusions were administered to 12 patients
during 18 cycles (5%); the rate of RBC transfusions was
similarly distributed among all dose levels.
Non-hematologic toxicity
Paclitaxel-related myalgia and peripheral neuropathy
were the most common noh-hematologic toxicities
(Table 5) together with alopecia, which was universal at
all the dose levels tested. Mild to moderate myalgia,
sometimes in association with neuropathy, was frequent,
especially for doses of P > 175 mg/m2; myalgia ap-
peared during the week following treatment and was
usually controlled with nonsteroidal anti-inflammatory
drugs.
Peripheral neuropathy was first seen at dose level 2
(with P dose of 155 mg/m2): it was generally mild and
mostly sensory, restricted to distal extremities. Periph-
eral neuropathy of grade 2 or greater occurred in 23% of
patients treated with P at 200 mg/m2. The majority of
these patients (58%) developed peripheral neuropathy
after two to three cycles (median 3, range 2-8). Two
patients treated at dose level 3 (with P at 175 mg/m2 and
C at 600 mg/m2) and one patient treated at dose level 7
(with P at 200 mg/m2 and C at 1,250 mg/m2) developed
grade 3 peripheral neuropathy, associated with weak-
ness and impairment of function, which was dose limit-
ing and required treatment discontinuation after three
(total P dose: 900 mg), four (total P dose: 1,320 mg) and
six (total P dose: 1,950 mg) cycles. Motor polyneurop-
athy slowly improved but peripheral paresthesia was still
present 11, 9 and 6 months after the last P administra-
tion.
Other non-hematologic toxicities were uncommon;
nausea and vomiting, probably because of the high-dose
glucocorticosteroids administered as premedication, was
rare, mucositis was infrequent and of only mild to
moderate degree.
One patient with a single liver metastasis, treated
with P at 200 mg/m2 and C at 1,500 mg/m2, developed
severe liver toxicity with jaundice after the second
course of therapy: hepatitis tests all yielded negative
results while liver biopsy demonstrated diffuse hepato-
cytic damage with intrahepatic cholestasis, compatible
Table 5. Grade 2 or greater non-hematologic toxicities.
Dose
level
1
2"
3
4
5
6
7
8
9
10
Dose P/C
(mg/m2)
135/750
155/750
175/600
175/750
200/750
200/1000
200/1250
200/1500
200/1750
200/2000
Peripheral
neuropathy
pts/cycles
with toxicity
0/0
1/7
3V5
0/0
2/2
6/11
2b/5
1/3
4/6
2/2
Myalgia
pts/cycles
with toxicity
1/2
1/1
4/4
3/4
5/11
5/9
2/3
8/17
6/8
3/3
Mucositis
pts/cycles
with toxicity
1/1
1/1
0/0
0/0
0/0
1/1
0/0
0/0
1/1
0/0
Eval-
uable
pts/
cycles
3/8
"6/20
4/12
7/35
9/41
9/36
6/31
8/36
20/97
8/36
• DLT in 2 pts.
b
 DLT in 1 pt.
with drug-induced toxicity. The patient was receiving
prophylactic oral ciprofloxacin and ketoconazole which
had not been given at the first cycle. The causal relation-
ship with study drug was classified as possible.
Four patients treated at dose levels 9 and 10 (with C
at 1,750 mg/m2 and 2,000 mg/m2) developed hemor-
rhagic cystitis requiring mesna administration and in-
creased post-treatment hydration.
Antitumor efficacy
Two patients were not evaluable for response because of
toxic death in one case and refusal of treatment in the
other, both after the first cycle. Among 78 evaluable
patients, the overall response rate was 38% (95% CI:
28%-50%) with 38% of patients showing tumour pro-
gression. Of 63 patients with measurable disease, 35%
achieved partial and 6% complete responses, for an
overall response rate of 41% (95% CI: 29%-54%). Ma-
jor responses were documented at a variety of sites
including liver (10 patients), lung (12 patients) and soft
tissue (14 patients).
The response rate in 36 patients receiving P and C as
salvage therapy was 25% (95% CI: 12%-^2%) while it
was 50% (95% CI: 34%-66%) with 9% of complete
remissions in 42 evaluable patients who received it as
initial treatment. In the latter group of patients, the
antitumour efficacy seemed to be lower in patients re-
ceiving less than 200 mg/m2 of P, with no response
among eight patients treated, while a higher response
rate of 60% was reported in patients receiving P at 200
mg/m2. In addition, the response rate was comparable
in the group treated with C at dosages of up to 1500 mg/
m2 or higher, while in patients pretreated with chemo-
therapy a lower response rate was reported in those
receiving less than 1500 mg/m2 of C (16% vs. 50%).
Overall, the median time to progression in responders
was 7.5 months (range 4 to 21+) with no difference in
duration of response between patients pretreated or non
pretreated with chemotherapy. The antitumor efficacy in
patients resistant to anthracyclines was poor, with
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objective responses in 2 of 25 patients (8%; 95% CI: 1%-
26%), while the response rate in patients who received
anthracyclines as adjuvant therapy was 37%.
Discussion
A variety of multidrug regimens with paclitaxel (P) are
currently under evaluation in different stages of breast
cancer. The high complete response rate achieved with P
and doxorubicin in patients with metastatic disease [8]
has established this combination as thus far the most
effective in advanced disease, and has prompted its
evaluation as adjuvant treatment. On the other hand,
the reported antitumour activity of P in patients resist-
ant to anthracyclines suggested that combinations with
P and C might be of value in this setting, as well as in
tumour types other than breast which are sensitive to
both antitumour agents.
The results of the present study indicate that P and C
can be given together without G-CSF at doses of 200
mg/m2 as a three-hour infusion and, respectively, 1750
mg/m2 i.v. bolus, to patients without prior chemother-
apy for metastatic disease. The addition of G-CSF from
the first course of therapy allowed the delivery of the
same doses also to patients with one prior regimen for
advanced disease. As in the other studies where the
combination was evaluated in pretreated patients, neu-
tropenia was dose-limiting [9, 10]. In the present study,
however, the use of a shorter infusion of three hours of P
and of a single i.v. bolus of C, instead of the one-hour
infusion or of the three daily consecutive doses of C, was
associated with a lower incidence of febrile neutropenia
requiring i.v. antibiotics. Overall, only 5% of cycles were
complicated by febrile neutropenia, increased to 20% at
the MTD but without documented severe infections or
toxic deaths. In the NCI study in which a 72-hour
infusion schedule was used, a higher incidence of febrile
neutropenia requiring i.v. treatment was observed, pos-
sibly related to the higher number of pretreated patients
as well as to the incidence of cumulative diarrhea and
damage to the intestinal mucosa [10].
Even though the impact of drug sequencing upon
toxicity was not an objective of this study, a sequence
analysis was undertaken in the six patients treated at
dose level 2 (with P at 155 mg/m2 and C at 750 mg/m2).
The first three patients at each dose level received P
immediately before C at cycle 1 and C before P at cycle
2; the ANC and Pit nadirs were 0.2 X 109/l (range 0.1 to
1.2 x 1O9/1) and 110 x 1O9/1 (range 95 to 245 x 1O9/1). In
the subsequent three patients who received the alternate
sequence, the ANC and Pit nadirs were 0.9 x 109/l
(range 0.01 to 1.4 x 109/l) and 160 x 109/l (range 79 to
166 x 109/l). These preliminary observations confirm the
results of the John Hopkins study where a higher admis-
sion rate for fever and a lower average nadir ANC were
observed in the courses in which P was given before C
[9]. Peripheral neuropathy was the main non-hemato-
logical toxicity; it was mainly sensory, cumulative and
occurred in 23% of patients receiving P at 200 mg/m2;
because of the higher incidence of peripheral neuro-
pathy observed with higher doses of P, rising to 26%
and 40% of grades 2 or 3 toxicity at 225 mg/m2 and 250
mg/m2 as a three-hour infusion [4, 12] and of the still
unproven higher efficacy of greater doses of P, it was
decided to keep the dose of P at 200 mg/m2 and to
escalate further only the dose of C. Nevertheless, three
patients developed severe motor polyneuropathy, which
was dose limiting and required treatment discontin-
uation, after cumulative doses of 900, 1320 and 1950
mg/m2.
In the present study, the overall response rate in 78
evaluable patients was 38% (95% CI: 28%-50%). The
overall response rate in patients non-pretreated for
metastatic disease was 50% (95% CI: 34%-66%) with
9% complete remissions while it was 25% in patients
with one prior regimen for advanced disease. These
results, like those of Kennedy et al. [9] who reported an
overall response rate of 28% in a population of heavily
pretreated anthracycline refractory patients, are com-
parable to those achieved with a similar dose of P given
as a three-hour infusion in patients with [3, 4, 13] or
without prior chemotherapy [12]. This suggests that the
addition of single i.v. doses of C does not improve
the antitumour activity of P when given at 200 mg/m2
as first-line therapy; the observation of an apparently
higher antitumour activity in the group of pretreated
patients receiving C at dosages equal or greater than
1500 mg/m2 (50% vs. 16%) suggest that significant doses
of C should be used in this subgroup. This observation is
also partly supported by the higher antitumour activity
of 55% reported in the NCI study where P was given as a
72-hour infusion and C was administered at the highest
dose tested of 2700 mg/m2 in patients mostly pretreated
with alkylating agents and/or anthracycline-containing
regimen [10].
The results achieved in studies assessing the anti-
tumour efficacy of P in patients with anthracycline-
resistant tumours are difficult to evaluate because of the
limited number of patients, differences in characteristics
of the disease, differences in prior treatment and in the
definition of resistance to anthracyclines. In this study,
the response rate in anthracycline-resistant patients
was disappointingly low (8%) and comparable to the
9% reported with single-agent P given as a three-hour
infusion [13]. It may be that prolonged infusions are
associated with better antitumour activity, as already
reported, with similar response rates in patients resist-
ant or not to anthracycline [3]. The small sample size of
these studies, however, does not permit ruling out a true
difference; this needs to be confirmed in further studies.
Preclinical in vitro data [14] in human breast carcinoma
cell lines suggest that maximal cytotoxicity may result
from prolonged paclitaxel infusions: two ongoing ran-
domized studies in metastatic breast cancer will defi-
nitely clarify the characteristics of toxicity and activity
of 3-, 24- or 96-hour infusions [15] and will define the
optimal schedule of P.
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In conclusion, this study demonstrates that P by
three-hour infusion can be given safely in combination
with significant doses of C on an outpatient basis;
however, the 50% overall response achieved in patients
non-pretreated for metastatic disease does not support
its use as first-line therapy due to the availability of other
more active combinations. The combination might be of
some benefit in Those patients who received adjuvant
anthracyclines and developed tumour recurrence at
least six months after the completion of treatment; in
this group of patient the overall response rate was 37%.
The 25% overall response rate and the acceptable profile
of toxicity observed at doses of P and C of 200 mg/m2
and 1750 mg/m2 in pretreated patients indicate that this
regimen might represent a valuable salvage treatment,
not only in breast cancer but also in other tumor types
sensitive to P and alkylating agents, such as ovary and
lymphoma, provided C is given at doses of at least 1500
mg/m2. The good PBSC mobilisation produced by P
and C followed by G-CSF suggest a further develop-
ment of this combination in sensitive neoplasia [16, 17]
as cytoreductive treatment before high-dose chemother-
apy with stem cell rescue.
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